Company intelligence / Profile preview

CorriXR Therapeutics

Newark, Delaware, United States

Ownership: Private
Development stage: Other

Overview

CorriXR’s lead program, CXR101, has demonstrated preclinical proof of concept for knocking out NRF2 to sensitize solid tumors to standard-of-care treatments. IND-enabling studies are ongoing with an IND submission targeted for March 2026. The approach aims to improve treatment efficacy and reduce side effects by altering the tumor microenvironment and overcoming drug resistance pathways in solid tumors.

Therapeutic areas: Oncology
Modalities: CRISPR-based therapyGene therapyLipid nanoparticle delivery therapy
Industry: Biotech

Drug pipeline

1 asset

CXR101

Preclinical

Partnerships

ChristianaCare Gene Editing Institute (R&D partnership)Helen F. Graham Cancer Center & Research Institute at ChristianaCare (clinical access/collaboration)

Beyond the preview

Go deeper on CorriXR Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorriXR Therapeutics.

Explore the full profile